Finland· FI-REL-REL15051
Xigris
A drotrecogin alfa (activated) product containing drotrecogin alfa, registered in Finland by Eli Lilly Nederland B.V..
Checked against Fimea (Finland) on
Informational only — not a medical device.
The record
At a glance
Fimea (Finland)- Active substance
- Drotrecogin alfa
- Manufacturer
- Eli Lilly Nederland B.V.
- Country
- Finland (FI)
- ATC code
- B01AD10
- ATC class
- Drotrecogin alfa (activated)
- Defined daily dose
- 40 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Drotrecogin alfa (activated) in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/39a7c77c-f48a-4392-8445-528eafeaa651 GET /v1/drugs/39a7c77c-f48a-4392-8445-528eafeaa651?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "40",
"form": "infuusiokuiva-aine, liuosta varten",
"route": null,
"ddd_unit": "mg",
"strength": "20 mg",
"atc_label": "drotrekogiini alfa (aktivoitu)",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/1/02/225/002",
"fimea_rel_id": "REL15051",
"authorised_at": "2002-08-22"
}See everything about drotrecogin alfa (activated).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.